Stockscreener 앱 받기
8.91
1.71%
0.15
시간 외 거래:
8.89
-0.02
-0.22%
전일 마감가:
$8.76
열려 있는:
$8.76
하루 거래량:
2.55M
Relative Volume:
0.42
시가총액:
$1.94B
수익:
$51.95M
순이익/손실:
$-265.94M
주가수익비율:
-6.1944
EPS:
-1.4384
순현금흐름:
$-216.89M
1주 성능:
+5.82%
1개월 성능:
+1.71%
6개월 성능:
-25.35%
1년 성능:
+18.33%
1일 변동 폭
$8.655
$9.00
1주일 범위
$8.33
$9.43
52주 변동 폭
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
8.91 | 1.91B | 51.95M | -265.94M | -216.89M | -1.4384 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix (OCUL) soars 10.4% ahead of business updates - MSN
Discipline and Rules-Based Execution in OCUL Response - Stock Traders Daily
Ocular's Axpaxli Cuts Risk Of Worsening In Late-Stage AMD Study - Sahm
H.C. Wainwright reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
New Ocular SVP gets 300,000 stock options in inducement grant - Stock Titan
Here is why Ocular Therapeutix (OCUL) is highly favored by hedge funds - MSN
Aug EndMonth: Can Ocular Therapeutix Inc maintain its current growth rateWeekly Gains Summary & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Large Ocular Therapeutix (OCUL) share gift to spouse disclosed - Stock Titan
William Blair reiterates Ocular Therapeutix stock rating on trial data By Investing.com - Investing.com Canada
Ocular Therapeutix Inc Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD - marketscreener.com
Ocular Therapeutix presents additional wet AMD trial data By Investing.com - Investing.com Australia
William Blair Maintains Ocular Therapeutix(OCUL.US) With Buy Rating - Moomoo
OCUL Reiterates by HC Wainwright & Co. -- Price Target Maintained at $21 - GuruFocus
What's Going On With Ocular Therapeutix Stock Monday?Ocular Therapeutix (NASDAQ:OCUL) - Benzinga
Positive Week 52 Data Released for Ocular Therapeutix (OCUL) - GuruFocus
Is Ocular Therapeutix (OCUL) Quietly Recasting Its Retinal Strategy Around Axpaxli’s Phase 3 Design Choices? - Yahoo Finance
Ocular Therapeutix™ Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI™ in Wet AMD - The Manila Times
Ocular Therapeutix Presents New SOL-1 Data Reinforcing AXPAXLI's Efficacy and Durability in Wet AMD at VBS Meeting - Quiver Quantitative
Ocular Therapeutix presents additional wet AMD trial data - Investing.com
Ocular Therapeutix™ Announces Additional Positive Week 52 - GlobeNewswire
Assessing Whether Ocular Therapeutix (OCUL) Looks Undervalued After Recent Mixed Share Price Performance - Yahoo Finance
Sectors Review: Is Ocular Therapeutix Inc undervalued by DCF analysis2026 Drop Watch & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Aug Rallies: Should I invest in Ocular Therapeutix Inc before earnings2026 Pullbacks & Safe Entry Zone Tips - baoquankhu1.vn
Ocular Therapeutix Stock Surges 10% Past $9 on Fresh SOL-1 Data Presentations for AXPAXLI - International Business Times Australia
Ocular Therapeutix (OCUL) Soars 10.4% Ahead of Business Updates - Insider Monkey
Chardan Capital Maintains Ocular Therapeutix (OCUL) Buy Recommendation - MSN
Market Leaders: Will Ocular Therapeutix Inc stock hit new highs in YEAR - baoquankhu1.vn
Update Recap: Will Ocular Therapeutix Inc benefit from geopolitical trendsTrade Signal Summary & Verified Momentum Stock Alerts - baoquankhu1.vn
Will Ocular Therapeutix’s (OCUL) AXPAXLI Data Spotlight Redefine Its Retinal Competitive Positioning? - Sahm
Behavioral Patterns of OCUL and Institutional Flows - Stock Traders Daily
OCULAR THERAPEUTIX, INC. (OCUL) - MSN
HC Wainwright lifts Ocular Therapeutix, Inc. (OCUL) price target following intravitreal implant FDA submission - MSN
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Sahm
Analysis Recap: How sensitive is Ocular Therapeutix Inc to inflation2026 Analyst Calls & Daily Technical Stock Forecast Reports - baoquankhu1.vn
OCUL Earning Date, Earning Analysis and Earning Prediction - intellectia.ai
Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds - Insider Monkey
Ocular lines up April talks on wet AMD trial data and retinal disease - Stock Titan
Ocular Therapeutix to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April - Bitget
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Ocular Therapeutix (NASDAQ:OCUL) Shares Up 9.3%Should You Buy? - marketbeat.com
OCULAR THERAPEUTIX (01477.HK) Completes First Patient Enrollment in Phase III Clinical Trial for OT-211 - AASTOCKS.com
Ocular Therapeutix, Inc. (NASDAQ:OCUL) Short Interest Up 34.2% in March - MarketBeat
Assenagon Asset Management S.A. Has $7.54 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Why Ocular Therapeutix (OCUL) Is Down 7.7% After Single‑Trial FDA Plan For AXPAXLI Superiority Claim - Sahm
What Ocular Therapeutix (OCUL)'s Single-Study FDA Bid After SOL-1 Superiority Means For Shareholders - Yahoo Finance
Vanguard reports zero holdings in Ocular Therapeutix (OCUL) - Stock Titan
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy - Investing.com
H.C. Wainwright reiterates Ocular Therapeutix stock rating at buy By Investing.com - Investing.com UK
H.C. Wainwright Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Ocular Therapeutix, Inc. (OCUL): A bull case theory - MSN
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):